These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29766637)

  • 1. Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study.
    Tinholt M; Garred Ø; Borgen E; Beraki E; Schlichting E; Kristensen V; Sahlberg KK; Iversen N
    J Thromb Haemost; 2018 Jul; 16(7):1347-1356. PubMed ID: 29766637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study.
    Tinholt M; Viken MK; Dahm AE; Vollan HK; Sahlberg KK; Garred O; Børresen-Dale AL; Jacobsen AF; Kristensen V; Bukholm I; Kåresen R; Schlichting E; Skretting G; Lie BA; Sandset PM; Iversen N
    BMC Cancer; 2014 Nov; 14():845. PubMed ID: 25407022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer.
    Tinholt M; Stavik B; Tekpli X; Garred Ø; Borgen E; Kristensen V; Sahlberg KK; Sandset PM; Iversen N
    Oncoimmunology; 2020 Sep; 9(1):1824644. PubMed ID: 33457104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation factor V in breast cancer: a p53-regulated tumor suppressor and predictive marker for treatment response to chemotherapy.
    Lind SM; Sletten M; Hellenes M; Mathelier A; Tekpli X; Tinholt M; Iversen N
    J Thromb Haemost; 2024 Jun; 22(6):1569-1582. PubMed ID: 38382738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
    Tinholt M; Vollan HK; Sahlberg KK; Jernström S; Kaveh F; Lingjærde OC; Kåresen R; Sauer T; Kristensen V; Børresen-Dale AL; Sandset PM; Iversen N
    Breast Cancer Res; 2015 Mar; 17(1):44. PubMed ID: 25882602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.
    Kariri YA; Joseph C; Kurozumi S; Toss MS; Alsaleem M; Raafat S; Mongan NP; Aleskandarany MA; Green AR; Rakha EA
    Breast Cancer Res Treat; 2020 Jan; 179(2):349-357. PubMed ID: 31679074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival.
    Michaelidou K; Ardavanis A; Scorilas A
    Breast Cancer Res Treat; 2015 Jul; 152(2):323-36. PubMed ID: 26099606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.
    Sizemore ST; Sizemore GM; Booth CN; Thompson CL; Silverman P; Bebek G; Abdul-Karim FW; Avril S; Keri RA
    Breast Cancer Res Treat; 2014 Jul; 146(1):25-40. PubMed ID: 24847890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
    Heikkinen T; Korpela T; Fagerholm R; Khan S; Aittomäki K; Heikkilä P; Blomqvist C; Carpén O; Nevanlinna H
    Breast Cancer Res Treat; 2013 Aug; 141(1):79-88. PubMed ID: 23974830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allelic imbalance at the HER2/TOP2A locus in breast cancer.
    Huijsmans CJ; van den Brule AJ; Rigter H; Poodt J; van der Linden JC; Savelkoul PH; Hilbink M; Hermans MH
    Diagn Pathol; 2015 May; 10():56. PubMed ID: 26022247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype.
    Lee K; Jang MH; Chung YR; Lee Y; Kang E; Kim SW; Kim YJ; Kim JH; Kim IA; Park SY
    Hum Pathol; 2017 Mar; 61():111-120. PubMed ID: 27989787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesothelin expression is associated with poor outcomes in breast cancer.
    Li YR; Xian RR; Ziober A; Conejo-Garcia J; Perales-Puchalt A; June CH; Zhang PJ; Tchou J
    Breast Cancer Res Treat; 2014 Oct; 147(3):675-84. PubMed ID: 25193277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of
    Liu Y; Liao XW; Qin YZ; Mo XW; Luo SS
    Biomed Res Int; 2020; 2020():9280841. PubMed ID: 32190689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
    Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
    Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients.
    Martínez-Galán J; Torres-Torres B; Núñez MI; López-Peñalver J; Del Moral R; Ruiz De Almodóvar JM; Menjón S; Concha A; Chamorro C; Ríos S; Delgado JR
    BMC Cancer; 2014 Feb; 14():59. PubMed ID: 24495356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dual prognostic role for the TGFβ receptors in human breast cancer.
    Hachim IY; Hachim MY; López-Ozuna VM; Ali S; Lebrun JJ
    Hum Pathol; 2016 Nov; 57():140-151. PubMed ID: 27445263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.